Invisible Particulate - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Invisible Particulate

Equipment and Processing Report

Untitled Document

Q: My drug failed a light-obscuration test, but after I filtered the drug for microscopic particle counting, I couldn’t see any significant particulate on the filter. What might have caused the failure, and why is it not visible?

A: One possibility is that what caused the failure was not solid particulate. A light-obscuration test can respond to droplets of suspended liquid (e.g., silicone oil in an aqueous product or water in an oil-based product), or even to air bubbles, as if they were solid, discrete particles. Air bubbles, of course, vanish completely upon filtration, water evaporates, and residual oil typically is not visible on the standard mixed-cellulose ester (MCE) filters used for USP <788> microscopic particle counts. Even on a membrane filter made of a smooth material such as polycarbonate, oil residue from a filtered product may not be visible.

The other possibility is that solid particulate was present in the liquid, but that its morphology prevents it from being seen easily on the filter. Very fine precipitates, as opposed to randomly sourced environmental particles, may be difficult, if not impossible, to see on an MCE filter because of its surface texture. Even on a smooth membrane filter, very fine particulate may form a layer that is too thin to be seen readily with ordinary oblique top lighting, even at a low angle. The same difficulties can occur with the stringy or amorphous precipitates that form in proteinaceous drug products, or with thin flakes of glass delamination. Using a smooth-surfaced membrane filter and a microscope equipped with episcopic or coaxial illumination (i.e., light directed down through the objective at a 90° angle to the filter surface) will allow particulates of these types, not apparent under other conditions, to be adequately visualized.

—Scott Stoeffler, senior research microscopist at McCrone Associates


If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here